Kornimate/medical-research-clean huggingface dataset:
exercise intervention - and impact on hospitalization

Conditions: Sarcopenia; Debility Due to Disease

Summary: skeletal muscle abnormalities (sarcopenia) and frailty are common complications seen in patients with end-stage liver disease. the presence of these complications portends poor prognosis. the purpose of this study is to assess the impact of a formal home based video strengthening program (rest) on sarcopenia and frailty. we also want to assess the impact of this exercise program on complication rates, hospitalization, on quality of life (qol) and on survival.


Eligibility criteria:
inclusion= waitlisted for liver transplant with poor 6mwt exclusion criteria include: age \< 18 years, recent hospitalization (within 14 days) due to decompensation, variceal bleeding in the previous 1 month, large esophageal varices without primary prophylaxis, active excessive alcohol intake (in the previous 3 months), current overt uncontrolled hepatic encephalopathy, hepatopulmonary syndrome with uncontrolled hypoxia, portopulmonary hypertension, inability to perform exercise, or marked symptomatic comorbidities (cardiac, pulmonary, renal). multiorgan transplant
a study to test a new decongestant in patients with allergic rhinitis following a nasal allergen challenge

Conditions: Allergic Rhinitis

Summary: an h3 receptor antagonist should reduce the congestion associated with allergic rhinitis. a nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.


Eligibility criteria:
inclusion criteria: * male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years. * subjects that respond to a ragweed nasal allergen challenge at screening. exclusion criteria: * history of asthma or fev1 \< 80% predicted. * significant concomitant disease or medications. * symptoms of allergic rhinitis within 2 weeks prior to screening.
efficacy and safety of early supported discharge for post-acute stroke patients in korea

Conditions: Stroke

Summary: the study aims to examine the effect of early supported discharge (esd) service on the functional outcomes and quality of life of acute stroke patients with mild to moderate disability in korea. the study is a double-armed prospective multi-centered, assessor-blinded randomized controlled trial comparing the effect of esd program with conventional rehabilitation program.

early supported discharge (esd) is a form of medical service applicable to acute stroke patients with mild to moderate disabilities. esd service was developed to facilitate patient to their daily livings at home, reduce the length of stay in the hospital with possibly better or equivalent outcomes for patients and caregivers. esd service has been proven to be non-inferior in the functional and quality of life measures as well as cost-effective, compared to the conventional rehabilitation service in many countries, however the effectiveness of esd service may differ among countries and medical, economical circumstances. this study aims to examine the effect of esd service on the acute stroke patients with mild to moderate disabilities in korea and demonstrate its feasibility as an alternative medical service option to those patients.

Eligibility criteria:
inclusion criteria: * patient who is over 20 years old * patient who had acute stroke and admitted to hospital (excludes tia) * patient who will be discharged to home within 30 days after onset * patient who has indwelling caregiver and is able to support in esd program * patient who's initial mrs is 1-3 * patient who's initial fac is 3 or above * patient who's initial k-nihss consciousness scores (1a,1b,1c) are all 0 exclusion criteria: * patient who had transient ischemic attack * patient who is medically unstable requiring intense treatment * patient who has indwelling urinary catheter * patient who is unable to intake food by mouth * patient who is initial mmse is below 15 * patient who has uncontrolled pain * patient who has psychobehavioral problems

Keywords: early supported discharge acute stroke
cognitive dysfunction in patients with cancer pain

Conditions: Cognitive Dysfunction

Summary: to investigate the occurrence of cognitive dysfunction in cancer patients with pain in china.analysis of patients with different cancer pain, different analgesic drugs and different treatments are associated with the severity of cognitive dysfunction, to provide relevant evidence for the next screening, prediction, prevention and treatment. in order to achieve the purpose of improving the quality of life of cancer patients.

cross-sectional survey in patients with cancer pain is used in the outpatient clinics and wards of five cancer hospitals in china. this study is to survey the incidence of cognitive dysfunction in chinese cancer patients, and the related factors of cognitive dysfunction, demographic characteristics (economic situation, education, gender, age), disease status (tumor type, staging) ), analgesic treatment (nrs score, with or without analgesic drugs, analgesic drug name, dose), anti-tumor treatment (with or without anti-tumor treatment, surgery, radiotherapy, chemotherapy, time interval from last treatment, chemotherapy drugs) and so on.

Eligibility criteria:
inclusion criteria: * malignant tumor patient with pain are confirmed by histopathology or cytology (nrs score ≥ 1); * understand chinese through verbal and written communication, read and write chinese, numbers, and complete questionnaire surveys; * male or female, age 18-75 years old; * ecog 0-2, expected to survive for more than 3 months; * no obvious dysfunction of heart, lung, liver, kidney, blood system (≤i degree); * patients voluntarily sign informed consent exclusion criteria: * pregnant women and lactating women. * also participate in clinical trials of drugs that have not been approved for marketing. * patients with depression (evaluated by the hamilton depression scale). * active bleeding or bleeding tendency. * serious or uncontrolled medical conditions and infected people. * patients with structural heart disease, such as coronary heart disease, unstable angina, especially patients with congestive heart failure and atrial fibrillation, atrial flutter history, and patients with hypertension, hypercoagulable state and severe cerebrovascular disease. * history of thromboembolic disease; long-term oral administration of aspirin and other anticoagulants. * preventive whole brain irradiation (pci). * bone marrow invasion or bone marrow metastasis. * patients with severe or uncontrollable mental illness.
the role of the duodenum in the pathogenesis of insulin resistance and type 2 diabetes mellitus

Conditions: Insulin Resistance and Type 2 Diabetes

Summary: in parallel with the increasing prevalence of obesity worldwide, type 2 diabetes mellitus (t2dm) has reached epidemic proportions. despite a multitude of available therapies, only bariatric surgery (e.g., roux-en-y gastric bypass (gbp)) has proven to be an effective long term treatment modality for morbid obesity. moreover, the majority of t2dm patients who undergo gbp experience normalization of their blood glucose and are able to discontinue their anti-diabetes medications soon after the procedure. the insulin resistant state commonly seen in non-diabetic obese subjects also improves after gbp. evidence from recent animal studies suggests that the rapid return to euglycemia seen in t2dm patients after gbp might in part result from excluding the duodenum from the flow of nutrients. with the use of enteral feeding tubes, we hope to better understand the factors in the human gut that may predispose obese individuals to the development of insulin resistance and t2dm.


Eligibility criteria:
inclusion criteria: inclusion criteria for lean, healthy control subjects: 1. fasting plasma glucose (fpg) \< 100 2. age 18 to 55 3. bmi 18.5 to 24.9 kg/m2 4. stable weight for prior 3 months inclusion criteria for prediabetic individuals: 1. based on american diabetes association criteria of fpg \> 100 and \<126 2. age 18 to 55 3. bmi 35 to 60 kg/m2 4. stable weight for prior 3 months inclusion criteria for diabetic individuals: 1. diagnosis of type 2 diabetes mellitus (t2dm) for \< 5 years 2. hemoglobin a1c \< 8% 3. age 18 to 55 4. bmi 35 to 60 kg/m2 5. stable weight for prior 3 months exclusion criteria: exclusion criteria for all study subjects: 1. use of any of the following medications: thiazolidinediones, dipeptidyl-peptidase iv (dpp-iv) inhibitors (e.g., sitagliptin), glp-1 analogs (e.g., exenatide). 2. subjects with t2dm who are unable to maintain adequate glycemic control (i.e., having a fasting blood glucose that exceeds 250mg/dl on two consecutive tests) while temporarily discontinuing their oral diabetes medications for the study and in whom the study physician determines insulin therapy would not be appropriate. 3. females with a positive pregnancy test 5. prior gastric, duodenal, proximal jejunal surgery or pancreas resection 6. known malabsorptive disorder 7. history of cancer in past 5 years 8. renal insufficiency defined by serum creatinine \> 1.5 mg/dl 9. hepatic enzyme elevations of greater than twice the upper limits of normal 10. current use of warfarin or clopidogrel 11. intercurrent infections 12. contraindication to nasogastric or nasojejunal feeding tube (e.g., deviated nasal septum, prior upper gastrointestinal bleed, or history of easy bleeding) 13. residence outside the greater nashville, tn area
staccato zaleplon single dose pharmacokinetics

Conditions: Healthy

Summary: the purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the staccato thermal aerosol system in healthy volunteers


Eligibility criteria:
inclusion criteria: * male and female subjects between the ages of 18 to 55 years, inclusive who are in good general health exclusion criteria: * subjects with a history of allergy or intolerance to zaleplon. subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.

Keywords: healthy adult volunteers
ehealth-based bavarian alternative detection of atrial fibrillation: a randomized controlled trial (ebrave-af)

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common arrhythmia in western countries and causes of up to one quarter of ischemic strokes. the randomized ehealth-based bavarian alternative detection of atrial fibrillation study (ebrave-af) tests the efficacy of an e-health based strategy for the detection of af. the e-health-based strategy consists of a smartphone-based photophlethysmographic (ppg) screening and an ecg-based validation.


Eligibility criteria:
inclusion criteria: * policy holders of a large health insurance company * age ≥50 years * cha2ds2-vasc ≥1 (females ≥2) exclusion criteria: * atrial fibrillation * oral anticoagulation
knowledge, attitudes, perceptions and behaviors of healthcare professionals and the general population regarding vaccination during febrile illness

Conditions: Febrile Illness

Summary: patients and healthcare professionals often lack adequate information regarding the possibility of vaccinating during febrile illnesses due to limited data. french guidelines on this topic remain vague, placing the responsibility for decision-making on healthcare professionals. this lack of clear guidance, combined with a perceived low urgency for vaccination in such cases, frequently leads to postponements, resulting in missed vaccination opportunities. by investigating the knowledge, attitudes, perceptions, and behaviors of both patients and healthcare professionals, the investigators can identify obstacles and leverage incentives to promote vaccination during mild febrile illnesses. this approach could help reduce missed opportunities and improve vaccine coverage overall.


Eligibility criteria:
inclusion criteria: * healthcare professionals : to administer vaccines as part of their usual practice * general population: adults aged 18 years old and over. exclusion criteria: * healthcare professionals: professionals that do not vaccinate patients in their usual practice. * general population : individuals under the age of 18 years old.

Keywords: vaccination immunization febrile illness mild fever efficacy safety
retrospective study in sarcoma patients

Conditions: Sarcoma of Bone; Sarcoma of Soft Tissue

Summary: the objectives of this trial is to evaluate efficacy and safety of treatment with trabectedin in a large cohort of german patients with soft tissue and bone sarcomas.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of trabectedin in any line of therapy. * age ≥18years at start of therapy with trabectedin * informed consent * patients already deceased may be included when the treating physician is able to determine the presumptive consent exclusion criteria: * no follow-up data available

Keywords: drug therapy treatment outcome adult
neurofeedback in decreasing acute radiotherapy-induced pain in patients with head and neck cancer

Conditions: Head and Neck Carcinoma

Summary: this pilot trial studies how well neurofeedback training works in decreasing acute radiotherapy-induced pain in patients with head and neck cancer. neurofeedback training is a type of therapy that uses electroencephalograph and a computer software program to measure brain wave activity. neurofeedback training may help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

primary objectives: i. determine the effects of an individualized loreta (low resolution electromagnetic tomography) z score neurofeedback program on changes in brain function using eeg (electroencephalography), qeeg (quantitative electroencephalography), and loreta from immediately before to after each session in patients with head and neck cancer undergoing radiotherapy and experiencing pain. secondary objectives: i. examine the effects of an individualized loreta z score neurofeedback program on perceptions of radiation-induced pain in head and neck cancer patients from immediately before neurofeedback training to immediately after neurofeedback training. ii. identify brain regions from qeeg and loreta that are associated with a non-pain state and then an acute pain state. iii. examine the relationship between the patient and their spouse or primary caregiver. outline: beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training once per day (qid) three times per week (tiw) for up to 6 treatments. patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training. after completion of study, patients are followed up at 1 week.

Eligibility criteria:
inclusion criteria: * patients must have the ability to understand and read english, sign a written informed consent, and be willing to follow protocol requirements * patients must not have pain \> 2 on a scale of 0 - 10 (self report) in the head and neck before starting radiotherapy * scheduled to undergo a 6 week course of radiotherapy for head and neck cancer * no plans to change the type of pain medication during the course of the study exclusion criteria: * patients who are taking any antipsychotic medications * patients with active central nervous system (cns) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy * patients who have ever been diagnosed with bipolar disorder or schizophrenia * patients with known, previously diagnosed head or neck pain from other pain syndromes or chronic pain requiring analgesics * patients with a history of seizure disorders
comparison of two ppos models for pituitary suppression

Conditions: Infertility, Female; Fertility Disorders

Summary: the scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. this study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.

this is a multicenter, randomized, controlled clinical study comparing two different progestogens for pituitary suppression in normo-responding patients undergoing controlled ovarian hyperstimulation (coh) for egg donation. patients will be recruited on the day they begin the egg donation program. before inclusion, patients must meet all inclusion and exclusion criteria and provide written informed consent. each patient will be assigned a patient code based on the treatment group they are included in. treatment with the assigned progestogens will start on the first day of coh. the standard protocol for egg donation will be followed, including stimulation with fshr (puregon®), pituitary suppression with either medroxyprogesterone acetate (progevera®) or desogestrel (cerazet®), and trigger with gnrh agonist (triptorelin acetate, decapeptyl®) 36 hours before oocyte retrieval. patients will continue taking the assigned progestogen throughout the coh period. oocyte quality will be assessed based on maturity and morphology, with mature oocytes classified as normal or good quality and abnormal oocytes categorized into intracytoplasmic and extracytoplasmic abnormalities. quality assessment will be performed by two blinded embryologists.

Eligibility criteria:
inclusion criteria: * bmi of 18-29,9 kg/m2 * ultrasound count of antral follicles prior to coh ≥ 12 follicles * meeting the criteria for inclusion in the egg donation program * normal karyotype and no active sexually transmitted diseases * no use of combined hormonal contraceptives one month before coh exclusion criteria: * patients excluded from the egg donation program * untreated sexually transmitted diseases, positive serology for hbv, hiv, hcv * blood disorders, neurodegenerative/psychiatric diseases, carriers of x-linked genetic diseases, oncological diseases, endometriosis. * oligomenorrhea (\<1 menstrual cycle in 3 months) * use of combined hormonal contraceptives before coh

Keywords: primed-progestin ovarian stimulation protocol quality of oocytes oocyte yield ovarian sensitivty index controlled ovarian hyperstimulation
admission hba1c in aneurysmal subarachnoid hemorrhage

Conditions: Hyperglycemia; Aneurysmal Subarachnoid Hemorrhage

Summary: in patients suffering from aneurysmal subarachnoid hemorrhage (asah), hyperglycemia is considered an adverse prognostic factor. glycated hemoglobin (or hba1c) can be measured to estimate the average plasma glucose concentration over prolonged periods of time, thus determination of glycated hemoglobin at admission after asah serves as an approximation of blood glucose levels in the weeks preceding aneurysm rupture. in this patient registry admission hba1c, clinical course and neurological outcome after 6 month are recorded, to determine whether elevated blood glucose levels prior to aneurysm rupture influence the clinical course and patient outcome after asah.

in patients suffering from aneurysmal subarachnoid hemorrhage (asah), hyperglycemia is considered an adverse prognostic factor. glycated hemoglobin (or hba1c) can be measured to estimate the average plasma glucose concentration over prolonged periods of time, thus determination of glycated hemoglobin at admission after asah serves as an approximation of blood glucose levels in the weeks preceding aneurysm rupture. in this patient registry admission hba1c within 72 hours after confirmed aneurysmal subarachnoid hemorrhage in patients aged over 18 years is determined and correlated with clinical course and neurological outcome after 6 month as determined by modified rankin score. additionally, patients are monitored for incidence of delayed cerebral ischemia (dci) and the incidence of new infarction on the discharge ct scan attributable to dci. general treatment of cerebral aneurysm and subarachnoid hemorrhage in all patients follows international guidelines.

Eligibility criteria:
inclusion criteria: * confirmed aneurysmal subarachnoid hemorrhage * admission within 72hours after hemorrhage * age \>18 years exclusion criteria: * non-aneurysmal sah * admission \>72hours after hemorrhage * age \<18 years

Keywords: hyperglycemia aneurysmal subarachnoid hemorrhage glycated hemoglobin outcome dci
phase i study of continuous infusion schedule of fmdc in hematologic malignancies

Conditions: Hematologic Malignancies

Summary: the goal of this clinical research study is to find the highest dose of tezacitabine (fmdc) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. the general safety and effectiveness of this drug will also be studied.

patients with leukemias that have relapsed from previous therapies have a low cure rate. hence the need to discover new antileukemic agents. tezacitabine is a nucleoside analogue with equivalent or even superior activity when compared with ara-c in leukemic cell lines. it has shown significant antitumor activity in vitro and in vivo tumor models. several phase i studies with various dosing schedules have been conducted in solid tumors where the dose-limiting toxicity (dlt) is mainly myelosuppression, usually a favorable feature for development of leukemia. in a phase i study in hematological malignancies, we used tezacitabine as a bolus infusion daily x 5. the dlt consisted of grade 3 cns toxicities and mucositis in 3/6 patients. the study is ongoing and we are currently evaluating a dose level of 7.5 mg/m2 as possible maximum tolerated dose (mtd). however, in view of the fact that tezacitabine is a cell cycle specific agent with a short terminal plasma half-life of 2 to 6 hours, a continuous infusion dosing schedule may enhance the activity and reduce the incidence of adverse effects of tezacitabine.

Eligibility criteria:
* patient with relapsed/refractory acute leukemias (aml, all, high-grade myelodysplastic syndromes, cmml in transformation with \>/= 10% peripheral blood/bone marrow blasts, cml in blast crisis), or patients with relapsed/refractory cll and an absolute neutrophil count of \>/= 1,000/ml and platelet count of \>/= 75,000/ml. * signed informed consent indicating that patients are aware of the investigational nature of this study, and in keeping with the policies of this hospital. the only acceptable consent form is attached at the end of this protocol. * age \>/= 15 years. * ecog performance status \</= 2. * no severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for study entry. * pregnant and/or lactating females are not eligible. * normal organ function (serum bilirubin £ 2 mg/dl, serum creatinine £ 2 mg/dl). patients with renal or liver dysfunction due to organ leukemic involvement may be eligible after discussion with the principle investigator. * patients must be off of all previous chemotherapy, immunotherapy, or radiotherapy for at least 2 weeks prior to entering this study, and must have recovered from all toxic effects, unless life-threatening increases in tumor burden occur.

Keywords: investigational chemotherapy hematologic malignancies nucleoside analogue